Spectrum Pharmaceuticals to Present Corporate Update at Rodman & Renshaw Annual Global Investment Conference in New York City on September 10th and at Morgan Stanley Global Healthcare Conference in New York City on September 11th
<0> Spectrum PharmaceuticalsShiv Kapoor, 702-835-6300Vice President, Strategic Planning & Investor Relations </0>
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company’s business strategy and commercial and development-stage programs will be given at the Rodman & Renshaw Annual Global Investment Conference being held at The Waldorf-Astoria in New York City. The Company presentation is on Monday, September 10, 2012, at 11:15 AM ET.
Spectrum also will be presenting at the Morgan Stanley Global Healthcare Conference being held at the Grand Hyatt in New York City. The Company presentation is on Tuesday, September 11th at 1:30 PM ET.
Live webcasts of Spectrum's corporate presentations will be available at .
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in oncology and hematology. Spectrum markets three oncology drugs ─ FUSILEV® (levoleucovorin) for Injection in the U.S.; FOLOTYN® (pralatrexate injection), also marketed in the U.S.; and ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use, for which the Company has worldwide marketing rights. Spectrum's strong track record in in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at .